公开(公告)号：US12122821B2

公开(公告)日：2024-10-22

申请号：US16510220

申请日：2019-07-12

Applicant: H. LUNDBECK A/S

Inventor： Brian Baker ,  Jeffrey T.L. Smith ,  John Latham

IPC: C07K16/18 ,  A61K39/00 ,  C07K16/26 ,  G01N33/50 ,  G01N33/66

CPC classification number: C07K16/18 ,  G01N33/5038 ,  G01N33/5088 ,  G01N33/66 ,  A61K2039/505 ,  C07K16/26 ,  C07K2317/76 ,  G01N2333/5753

Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.

公开(公告)号：US20240306616A1

公开(公告)日：2024-09-19

申请号：US18442444

申请日：2024-02-15

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Kara L. Olson ,  Eric Smith ,  Ka-Man Venus Lai ,  Andrew J. Murphy ,  Gavin Thurston ,  Dayong Guo

IPC: A01K67/0278 ,  A01K67/0276 ,  C07K14/725 ,  C12N5/071 ,  C12N15/85 ,  G01N33/50

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K14/7051 ,  C12N5/0602 ,  C12N15/8509 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0337 ,  Y02A50/30

Abstract: Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.

公开(公告)号：US12085542B2

公开(公告)日：2024-09-10

申请号：US17413256

申请日：2019-12-04

Applicant: KABUSHIKI KAISHA YAKULT HONSHA

Inventor： Takuya Akiyama ,  Kazunori Matsuda ,  Junji Fujimoto

IPC: G01N3/40 ,  G01N33/483 ,  G01N33/50

CPC classification number: G01N3/40 ,  G01N33/483 ,  G01N33/5088 ,  G01N2203/0076

Abstract: For providing a method capable of physically and objectively evaluating the consistency and state of a stool, provided is a method for measuring a stool consistency with a texture analyzer provided with a probe, the probe having a shape capable of measuring a consistency of a stool in a liquid form and in a solid form.

公开(公告)号：US12082565B2

公开(公告)日：2024-09-10

申请号：US17348907

申请日：2021-06-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Susannah Brydges ,  Yajun Tang ,  Yang Liu ,  Jingtai Cao ,  Carmelo Romano

IPC: C12N5/00 ,  A01K67/0276 ,  A01K67/0278 ,  C07K14/47 ,  C12N15/85 ,  G01N33/50 ,  G01N33/68

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  C07K14/47 ,  C12N15/8509 ,  G01N33/5088 ,  G01N33/6893 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0306 ,  A01K2267/0393 ,  C12N2015/8527 ,  C12N2015/8536 ,  C12N2510/00 ,  C12N2800/30 ,  C12N2830/008

Abstract: Non-human animals suitable for use as animal models for Retinoschisis are provided. In some embodiments, provided non-human animals are characterized by a disruption in a Retinoschisin-1 locus. In some embodiments, provided non-human animals are characterized by a mutant Retinoschisin-1 gene. The non-human animals may be described, in some embodiments, as having a phenotype that includes the development of one or more symptoms or phenotypes associated with Retinoschisis. Methods of identifying therapeutic candidates that may be used to prevent, delay or treat Retinoschisis or eye-related diseases, disorders or conditions are also provided.

公开(公告)号：US20240280565A1

公开(公告)日：2024-08-22

申请号：US18562797

申请日：2022-05-19

Applicant: GENOSKIN

Inventor： Emeline PAGES ,  Pascal DESCARGUES ,  Nicolas GAUDENZIO

IPC: G01N33/50

CPC classification number: G01N33/5088

Abstract: This relates to an in vitro method intended to determine the inflammatory potential of a substance including the steps of: ia) administration to a skin explant, topically or by subcutaneous injection, of a composition including the substance; where the skin explant includes the epidermis, the dermis and the skin appendages, as well as a thickness of at least 5 millimeters of hypodermis; ib) determination of the inflammatory response within the skin explant; ic) determination of the level of mast cell degranulation within the skin explant; and ii) determination of the inflammatory potential of the substance and its association or not with an allergic or pseudoallergic potential.

公开(公告)号：US12060406B2

公开(公告)日：2024-08-13

申请号：US17179074

申请日：2021-02-18

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K39/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240263147A1

公开(公告)日：2024-08-08

申请号：US18598152

申请日：2024-03-07

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.

Inventor： Yaakov NAHMIAS ,  Mohammad GHOSHEH ,  Avner EHRLICH

IPC: C12N5/071 ,  C12N5/00 ,  C12N5/077 ,  G01N33/50

CPC classification number: C12N5/0697 ,  C12N5/0062 ,  C12N5/0657 ,  C12N5/069 ,  G01N33/5088 ,  C12N2513/00

Abstract: The present invention provides a method of treating a disease or disorder characterized by electro-mitochondrial desynchronization in a subject in need thereof, comprising confirming the disease or disorder is characterized by electro-mitochondrial desynchronization in the subject and administering an agent that modulates mitochondrial calcium concentration and/or increases mitochondrial calcium channel activity in a tissue of the disease or disorder in the subject. Multichambered cardiac organoids comprising cardiomyocytes and endothelial cells and at least two chambers beating in synchrony are provided. Further provided are methods of using the multichambered cardiac organoid, methods of producing a cardiac organoid. Systems for making measurements within cellular aggregates or tissues and the use of same for testing therapeutic agents is also provided.

公开(公告)号：US11993785B2

公开(公告)日：2024-05-28

申请号：US16533300

申请日：2019-08-06

Applicant: Wake Forest University Health Sciences

Inventor： Aleksander Skardal ,  Casey Cuvan Clark

IPC: C12N5/071 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00 ,  C12M3/00 ,  C12N5/00 ,  C12N13/00 ,  G01N33/50

CPC classification number: C12N5/0062 ,  B33Y10/00 ,  B33Y70/00 ,  B33Y80/00 ,  C12M21/08 ,  C12N5/0697 ,  C12N13/00 ,  G01N33/5088 ,  C12N2513/00

Abstract: Provided are methods of preparing organoids and compositions for use in such methods. In some embodiments, a method of depositing a plurality of the cells into a reservoir are provided, the method comprising depositing a gelatin composition into a reservoir; adding a composition comprising a plurality of cells into the gelatin composition, wherein the composition is added into the gelatin composition at a position below the surface of the gelatin composition and at least a portion of the composition and/or plurality of cells are suspended in the gelatin composition; curing at least a portion of the composition comprising the plurality of cells in the gelatin composition; and removing at least a portion of the gelatin composition in the reservoir, thereby depositing the plurality of cells in the reservoir.

公开(公告)号：US11965013B2

公开(公告)日：2024-04-23

申请号：US17514743

申请日：2021-10-29

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: C07K14/70 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：US20240060052A1

公开(公告)日：2024-02-22

申请号：US18500552

申请日：2023-11-02

Applicant: VALO HEALTH, INC.

Inventor： Roozbeh Aschar-Sobbi ,  Isabella Pallotta

IPC: C12N5/071 ,  C12N5/077 ,  C12M3/00 ,  C12M1/32 ,  C12M1/34 ,  C12M1/42 ,  G01N33/50

CPC classification number: C12N5/0697 ,  C12N5/0658 ,  C12N5/0656 ,  C12M21/08 ,  C12M23/12 ,  C12M41/46 ,  C12M35/02 ,  G01N33/5088 ,  G01N33/5061 ,  C12M35/08 ,  C12N2533/54 ,  C12N2513/00 ,  C12N2533/56

Abstract: Embodiments described herein relate generally to a three-dimensional ex vivo skeletal muscle tissue comprising a hydrogel and a plurality of cells that includes skeletal muscle cells, at least a portion of the cells being encapsulated inside the hydrogel. In some embodiments, the skeletal muscle tissue is characterized by one or more contractions in response to an electrical and/or chemical stimulation.